Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia
A Quintás-Cardama, HM Kantarjian… - Cancer control, 2009 - journals.sagepub.com
Background Although the vast majority of patients with chronic myeloid leukemia (CML)
respond to the tyrosine kinase inhibitor (TKI) imatinib mesylate, resistance might occur de …
respond to the tyrosine kinase inhibitor (TKI) imatinib mesylate, resistance might occur de …
Dasatinib in chronic myeloid leukemia: a review
DG Aguilera, AM Tsimberidou - Therapeutics and Clinical Risk …, 2009 - Taylor & Francis
Deregulated BCR-ABL tyrosine kinase (TK) activity is the molecular marker for chronic
myeloid leukemia (CML), which provides an identifiable target for developing therapeutic …
myeloid leukemia (CML), which provides an identifiable target for developing therapeutic …
Imatinib mesylate
CF Waller - Small Molecules in Oncology, 2009 - Springer
Abstract IMATINIB MESYLATE (Gleevec, Glivec [Novartis, Basel, Switzerland], formerly
referred to as STI571 or CGP57148B) represents the paradigm of a new class of anticancer …
referred to as STI571 or CGP57148B) represents the paradigm of a new class of anticancer …
Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells
J Klawitter, DJ Kominsky, JL Brown… - British journal of …, 2009 - Wiley Online Library
Background and purpose: Early detection of resistance development is crucial for imatinib‐
based treatment in chronic myeloid leukaemia (CML) patients. We aimed to distinguish …
based treatment in chronic myeloid leukaemia (CML) patients. We aimed to distinguish …
Next generation oncology drug development: opportunities and challenges
The optimal development of novel molecularly targeted agents for the treatment of cancer
requires a re-evaluation of the current drug development paradigm. Selection of patients …
requires a re-evaluation of the current drug development paradigm. Selection of patients …
Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study
J Klawitter, N Anderson, U Christians, D Leibfritz… - British journal of …, 2009 - nature.com
The goal of this study was to evaluate the time course of metabolic changes in leukaemia
cells treated with the Bcr-Abl tyrosine kinase inhibitor imatinib. Human Bcr-Abl+ K562 cells …
cells treated with the Bcr-Abl tyrosine kinase inhibitor imatinib. Human Bcr-Abl+ K562 cells …
In vitro biology of human myeloid leukemia
H Mayani, E Flores-Figueroa, A Chávez-González - Leukemia research, 2009 - Elsevier
For about 40 years, the biology of human myeloid leukemia (ML) has been studied in
different in vitro systems. Throughout this time, semisolid colony assays, Dexter-type long …
different in vitro systems. Throughout this time, semisolid colony assays, Dexter-type long …
Valproic acid enhances bosutinib cytotoxicity in colon cancer cells
Unbalanced histone deacetylase (HDAC) hyperactivity is a common feature of tumor cells.
Inhibition of HDAC activity is often associated with cancer cell growth impairment and death …
Inhibition of HDAC activity is often associated with cancer cell growth impairment and death …
Annexin A5-functionalized liposomes for targeting phosphatidylserine-exposing membranes
B Garnier, A Bouter, C Gounou, KG Petry… - Bioconjugate …, 2009 - ACS Publications
Long-circulating liposomes functionalized with cell-targeting elements and loaded with
bioactive compounds present high interest as drug delivery nanosystems. We present here …
bioactive compounds present high interest as drug delivery nanosystems. We present here …
Хронический миелолейкоз-до и после применения иматиниба (часть II)
ЕГ Ломаиа, НС Лазорко, Е Саламатова… - …, 2009 - cyberleninka.ru
Механизмы действия ИТК ИМ. ИМ, конкурентно присоединяясь к АТФ-связывающему
карману SH1 домена белка р210BCR-ABL, блокирует ТК в ее неактивной конформации …
карману SH1 домена белка р210BCR-ABL, блокирует ТК в ее неактивной конформации …